PUBLICATIONS | PRESS RELEASES | < BACK

Press Releases

XX/XX/2009
Calixa Therapeutics Announces Promising Phase 1 Results for CXA-101,

A Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-pseudomonal Activity